Skip to main content
. 2022 Mar 24;13:861670. doi: 10.3389/fimmu.2022.861670

Figure 8.

Figure 8

VISTA-/- mice have significantly worse survival and morbidities following septic challenge. (A) 14-day survival following CLP [WT: n = 28, VISTA-/-: n = 26]. (B) Creatine kinase activity [WT-sham: n = 9, WT-CLP: n = 9, VISTA-/-sham: n = 10, VISTA-/- -CLP: n = 10]. (C) blood urea nitrogen [WT-sham: n = 4, WT-CLP: n = 9, VISTA-/-sham: n = 5, VISTA-/- -CLP: n = 8]. (D) α-Amylase activity [WT-sham: n = 5, WT-CLP: n = 6, VISTA-/-sham: n = 5, VISTA-/- -CLP: n = 6]. (E) Direct bilirubin concentration [WT-sham: n = 3, WT-CLP: n = 3, VISTA-/-sham: n = 3, VISTA-/- -CLP: n = 4]. (F) alanine aminotransferase activity [WT-sham: n = 4, WT-CLP: n = 8, VISTA-/-sham: n = 4, VISTA-/- -CLP: n = 8]. (G) Aspartate aminotransferase activity [WT-sham: n = 4, WT-CLP: n = 8, VISTA-/-sham: n = 4, VISTA-/- -CLP: n = 8] from plasma samples of wild-type and VISTA-/- mice. (B–G) Summary graphs show mean ± SEM; significance *p < 0.05; **p < 0.01.